SBIR/STTR Research Award
SNET2-Based Photodynamic Occlusion of Ocular Vessels
Award amount
$677,110Program and phase
SBIR · Phase IIAward year
1997Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Pdt Pharmaceuticals
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Neovascularization is associated with two ocular disorders, macular degeneration and diabetic retinconditions are high profile disorders that have significant association with visual impairments andare only preventative measures taken by clinicians to slow the progression of the diseases. No curatfound despite intensive research. Later photocoagulation is the current methodology for the treatmenin the eye. However, normal tissues and vessels adjacent to the targeted site are irreversibly damagheat. The ideal therapeutic modality would provide for highly selective and finely controlled destrublood vessels and/or area while minimizing damage to adjacent normal tissues. It is the aim of thispreliminary investigations on the use of photodynamic therapy (PDT) using tin ethyl etiopurpurin (Snof neovascularization in the eye. PDT holds promise as a more efficacious treatment modality than thphotocoagulation due to its low energy, non thermal light activation of a photosensitizer leading todestruction, thus sparing normal tissues. If the data resulting from Phase I studies looks efficaciodevelopment can be pursued in Phase II to determine optimum combinations of photosensitizer and lighmaximum therapeutic benefit.
Technology keywords
Not reported